Gyre Therapeutics, Inc. GYRE Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Revenue by Business | ||||
| Gyre Pharmaceuticals | $116.59M+10.2% | $105.76M-6.8% | $113.45M— | |
| Other Nonoperating Income Expense by Business | ||||
| Gyre | -$33K+90.2% | -$336K-23.5% | -$272K— | |
| Gyre Pharmaceuticals | -$1.47M-10.8% | -$1.33M-6.7% | -$1.25M— | |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest by Business | ||||
| All Other Segments | -$19K— | —— | -$3.29M— | |
| Gyre | -$5.19M— | —— | -$97.94M— | |
| Gyre Pharmaceuticals | $15.09M-9.6% | $16.7M+6.0% | $15.75M— | |
| Operating Income by Business | ||||
| All Other Segments | -$19K— | —— | -$3.29M-2,428% | |
| Gyre | -$8.49M-44.9% | -$5.86M+93.4% | -$88.4M— | |
| Gyre Pharmaceuticals | $19.99M-9.2% | $22.02M-11.8% | $24.95M— | |
| Operating Expenses by Business | ||||
| All Other Segments | $19K— | —— | $3.29M+2,428% | |
| Gyre | $8.49M+44.9% | $5.86M-93.4% | $88.4M— | |
| Gyre Pharmaceuticals | $97.49M+16.4% | $83.74M-0.7% | $84.36M— | |
| Income Tax Expense Benefit by Business | ||||
| Gyre Pharmaceuticals | $4.55M-14.4% | $5.32M-37.5% | $8.51M— | |
| Cost of Goods Sold by Business | ||||
| Gyre Pharmaceuticals | $5.42M+39.4% | $3.88M-16.2% | $4.64M— | |
| Total Assets by Business | ||||
| All Other Segments | $1.44M-53.5% | $3.11M— | —— | |
| Gyre | $94.58M+116% | $43.72M— | —— | |
| Gyre Pharmaceuticals | $511.93M+14.6% | $446.76M— | —— | |
| Selling And Marketing Expense by Business | ||||
| Gyre Pharmaceuticals | $65.18M+13.3% | $57.51M-6.0% | $61.16M— | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||
| Gyre Pharmaceuticals | $12.5M+11.4% | $11.22M-18.1% | $13.7M— | |
| Gyre | $1.2M+49.4% | $800K+876% | $82K— | |
| General And Administrative Expense by Business | ||||
| All Other Segments | $19K— | —— | $576K+343% | |
| Gyre | $7.29M+44.2% | $5.06M-3.0% | $5.21M— | |
| Gyre Pharmaceuticals | $13.49M+22.1% | $11.05M+24.6% | $8.87M— | |
| Interest Income Expense Net by Business | ||||
| Gyre | $621K+168% | $232K— | —— | |
| Gyre Pharmaceuticals | $1.13M-14.8% | $1.32M+26.5% | $1.04M— | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||
| Gyre Pharmaceuticals | $1.19M-49.7% | $2.37M-72.2% | $8.52M— | |
| Allocated Share Based Compensation Expense by Business | ||||
| Gyre | $2.61M+214% | $831K-81.5% | $4.49M— | |
| Gyre Pharmaceuticals | $4.55M— | —— | $2.79M— | |
| Fair Value Adjustment Of Warrants by Business | ||||
| Gyre | -$2.71M+62.2% | -$7.17M-177% | $9.26M— | |
| Revenue (Gross) by Product | ||||
| Contiva | $5.52M— | —— | —— | |
| Concentration Risk % by Product | ||||
| Contiva | 11.9%— | —— | —— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||
| Nanjing | 280— | —— | —— | |
| Shanghai | 896— | —— | —— | |
| Zhengzhou | 720— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
